Merck's flagship cancer drug, Keytruda, is poised to maintain robust revenue despite impending patent expiry risks, bolstered by new indications and the anticipated 20-year monopoly of KEYTRUDA QLEX. The pharmaceutical giant also benefits from significant growth in its Animal Health/Livestock segment, recording high single-digit increases. Furthermore, the company's new drug Winrevair is experiencing triple-digit growth, diversifying revenue streams. Analysts highlight Merck's healthy balance sheet, secure dividend payments, and reasonable valuation. This strong financial standing, coupled with resilient product performance, underpins a positive investment thesis. A pullback to the $100-$110 range or 50-day moving average levels is suggested as an opportune buying point for the stock.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis